GGrantIndex
← Search

Liquid Biopsy Core

$204,368P30FY2025CANIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

PROJECT SUMMARY – Liquid Biopsy Shared Resource The mission of the USC Norris Comprehensive Cancer Center (NCCC) Liquid Biopsy Shared Resource (LBC) is to provide a state-of-the-art multi-platform facility for capture and analysis of circulating tumor cells (CTCs) and matched plasma nucleic acids for cancer research. NCCC Administration oversees LBC with Amir Goldkorn MD continuing in his role as the faculty Director and founder in 2015. Goldkorn provides the strategic direction for LBC, overseeing technology, operations, and financial management. LBC is located in NCCC wet lab research space. During the current grant cycle, noteworthy enhancements include: 1) expanded CTC enrichment platforms from 5 to 12; 2) added new microfluidic cell separation systems, an automated slide stainer and RareCyte high-content CTC analysis and recovery system; 3) developed new workflows to combine recovery of single CTCs for whole genome amplification and gene copy number analysis, rapid enrichment of live CTCs for RNAseq, chip array profiling of plasma cfDNA methylation, and CTC immunofluorescence assays; 4) added parallel cell-free DNA banking and non-EpCAM-dependent CTC enrichment for EpCAM-poor tumors; and 5) developed cost-effective workflows. In the next grant cycle, LBC will be expanding research partnerships with R&D teams at various industry partners to co-develop exciting new liquid biopsy biomarker assays with strong potential for commercialization. During the current grant period from 2015-2020, LBC served 23 full NCCC members in 3 research programs – Translational and Clinical Sciences (TACS), Tumor Microenvironment (TME), and Genomic and Epigenomic Regulation (GER), resulting in 20 intramural and extramural funding applications, 15 of which were funded for $6.75M in direct costs. Since 2015, LBC has contributed to 5 published papers and 11 abstracts and processed 5,396 blood samples. The anticipated annual budget of LBC in the first year of the next grant cycle is $400,712, yet the CCSG request is $134,712. Accordingly, LBC leverages extensive institutional and recharge support and seeks only 34% from CCSG funds.

View original record on NIH RePORTER →